Intensity of intravitreal ranibizumab treatment for age-related macular degeneration may be linked to vascular adverse events, but not to an increased risk of mortality, according to researchers.The researchers conducted a meta-analysis of 11 randomized trials that comprised 6,596 patients with AMD. The trials selected compared systemic safety among varied intensities of ranibizumab (Lucentis, Genentech) treatment for AMD.